

What's new?

May saw a major reversal in equities as global markets rebounded significantly following a subdued month in April. With global economic data suggesting a moderating story, investors remain optimistic about a soft landing with a reasonable interest rate policy.

Here's how **biotech** performed.

- Total market capitalisation of **\$152.25bn** (increase of 1.5%).
- Total trading volume of **\$6.69bn** (increase of 45.1%).
- **56% of biotech companies** were performance positive or neutral.

Top biotech performers for May 2024.

MC (\$)	TICKER	NAME	1M (%)	3M (%)	12M (%)	MONTHLY VOL (\$)	VOL CHANGE (%)
\$82.96m	LTP	LTR PHARMA LIMITED	128.30	116.07	75.36	\$6.26m	448.94
\$44.15m	BDX	BCAL DIAGNOSTICS LIMITED	88.17	94.44	84.21	\$1.19m	4.26
\$1.27b	CU6	CLARITY PHARMACEUTICALS LTD	83.39	73.33	161.99	\$202.79m	177.02
\$57.48m	CYP	CYNATA THERAPEUTICS LIMITED	67.50	81.08	157.69	\$1.02m	0.87
\$250.1m	DXB	DIMERIX LIMITED	45.59	120.00	135.71	\$68.29m	112.55

Biotech averages by market cap segment for May 2024.

SEGMENT	MC (\$)	1M (%)	3M (%)	12M (%)	VOL (\$)	VOL CHANGE (%)
\$1bn+	\$29b	27.49	80.92	96.89	\$1.26b	62.33
\$500m - \$1bn	\$640.83m	5.59	18.92	13.94	\$24.38m	-16.46
\$100m - \$500m	\$266m	2.66	10.04	12.44	\$15.81m	91.95
\$10m - \$100m	\$27.26m	7.86	2.14	4.46	\$1.19m	56.58
\$0 - \$10m	\$6.13m	-12.51	-12.80	8.82	\$0.17m	65.51

(1) Company updates.

Here's how biotech companies performed for the month.

RANK	CHANGE	MC (\$)	TICKER	NAME	1M (%)	3M (%)	12M (%)	MONTHLY VOL (\$)	VOL CHANGE (%)
1	0	\$134.5b	CSL	CSL LIMITED	1.9	-1.7	-2.1	\$5.11b	44.29
2	0	\$5.26b	TLX	TELIX PHARMACEUTICALS LIMITED	22.4	47.9	79.7	\$487.86m	15.27
3	0	\$2.69b	NEU	NEUREN PHARMACEUTICALS LIMITED	15.4	8.9	-13.3	\$255.28m	103.00
5	1	\$1.27b	CU6	CLARITY PHARMACEUTICALS LTD	83.4	73.3	162.0	\$202.79m	177.02
4	0	\$1.27b	MSB	MESOBLAST LIMITED	14.4	276.3	258.1	\$263.92m	-27.96
6	-1	\$758.57m	CUV	CLINUVEL PHARMACEUTICALS LIMITED	5.3	16.2	-0.7	\$24.4m	-48.21
7	2	\$523.09m	IMM	IMMUTEP LIMITED	5.9	21.6	28.6	\$24.36m	15.28
9	1	\$466.61m	PYC	PYC THERAPEUTICS LIMITED	6.1	34.6	-8.7	\$11.48m	95.65
10	2	\$441.04m	BOT	BOTANIX PHARMACEUTICALS LTD	34.9	65.7	52.6	\$34.99m	134.84
8	-1	\$490.43m	IMU	IMUGENE LIMITED	-21.2	-46.4	-39.1	\$32.27m	-2.19
11	-3	\$427.07m	MYX	MAYNE PHARMA GROUP LIMITED	-25.9	-25.9	-18.0	\$38.93m	126.39
12	1	\$361.83m	AVH	AVITA MEDICAL INC.	13.3	-45.4	-29.8	\$34.71m	27.64
13	-2	\$351.29m	OPT	OPTHEA LIMITED	-18.4	-22.7	-10.5	\$11.83m	18.57
14	0	\$291.97m	AFP	AFT PHARMACEUTICALS LIMITED	0.4	-9.7	-14.9	\$0.24m	232.67
17	-1	\$243.41m	RAC	RACE ONCOLOGY LTD	17.9	74.1	76.2	\$4.25m	19.49
15	2	\$250.1m	DXB	DIMERIX LIMITED	45.6	120.0	135.7	\$68.29m	112.55
16	-1	\$246.41m	PBP	PROBIOTEC LIMITED	6.3	10.2	4.5	\$10.98m	109.91
18	0	\$189.31m	ARX	AROA BIOSURGERY LIMITED	11.8	0.9	-34.5	\$6.16m	169.42
19	0	\$136.99m	TRJ	TRAJAN GROUP HOLDINGS LIMITED	-8.8	-9.7	-24.4	\$4.43m	478.38
20	3	\$136.16m	GSS	GENETIC SIGNATURES LIMITED	6.6	28.1	80.2	\$2.38m	268.83
21	-1	\$129.58m	PIQ	PROTEOMICS INTERNATIONAL LABORATORIES LTD	-10.2	-6.7	10.2	\$3.04m	-32.00
22	0	\$125.98m	VLS	VITA LIFE SCIENCES LIMITED..	-1.7	3.7	21.6	\$0.85m	-82.78
23	-2	\$118.31m	RCE	RECCE PHARMACEUTICALS LTD	-11.4	27.2	10.4	\$0.87m	-56.77
24	0	\$115.52m	ALA	AROVELLA THERAPEUTICS LIMITED	0.0	-27.3	0.0	\$3.03m	-57.46
25	4	\$94.57m	AGN	ARGENICA THERAPEUTICS LIMITED	35.1	24.2	54.0	\$4.64m	49.15
27	12	\$82.96m	LTP	LTR PHARMA LIMITED	128.3	116.1	75.4	\$6.26m	448.94
26	-1	\$87.59m	PAR	PARADIGM BIOPHARMACEUTICALS LIMITED..	-13.8	-28.6	-43.2	\$3.45m	24.52
30	-2	\$73.24m	PAA	PHARMAUST LIMITED	-2.3	-40.8	82.6	\$9.32m	97.37
33	-1	\$66.71m	PER	PERCHERON THERAPEUTICS LIMITED	15.7	-6.9	37.3	\$1.24m	-31.97
28	-2	\$78.5m	OCC	ORTHOCELL LIMITED	-6.4	-13.1	-11.0	\$1.14m	1.61
29	1	\$74.79m	PEB	PACIFIC EDGE LIMITED	18.4	12.5	-9.1	\$0.07m	766.18
32	-1	\$71.3m	BIO	BIOME AUSTRALIA LIMITED	15.5	-14.1	59.5	\$1.71m	-24.08
31	-4	\$71.98m	ACW	ACTINOGEN MEDICAL LIMITED	-8.1	-10.9	33.6	\$1.26m	-18.45
35	6	\$57.48m	CYP	CYNATA THERAPEUTICS LIMITED	67.5	81.1	157.7	\$1.02m	0.87
34	-1	\$59.14m	ADO	ANTEOTECH LTD	14.3	-17.2	-31.4	\$1.51m	-10.42
37	-2	\$50.53m	BIT	BIOTRON LIMITED	-1.8	-25.0	-44.9	\$0.56m	-87.49
36	0	\$53.69m	CTE	CRYOSITE LIMITED	25.9	67.2	78.3	\$1.23m	258.04
38	-4	\$47.38m	SPL	STARPHARMA HOLDINGS LIMITED	-8.0	-11.5	-34.3	\$1.42m	18.80
44	-2	\$34.22m	IDT	IDT AUSTRALIA LIMITED	9.9	7.5	-9.1	\$0.67m	19.81
40	3	\$38.55m	COV	CLEO DIAGNOSTICS LTD	35.1	47.1	42.9	\$1.04m	256.87
43	-6	\$36.24m	PTX	PRESCIENT THERAPEUTICS LIMITED	-13.5	-6.3	-30.8	\$0.9m	8.00
41	-1	\$37.72m	LGP	LITTLE GREEN PHARMA LTD	4.0	-3.7	-13.3	\$0.4m	28.25
42	-4	\$37.11m	MVP	MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED	-9.6	-46.9	-44.4	\$1.49m	71.68

(2) Company updates.

Here's how biotech companies performed for the month.

RANK	CHANGE	MC (\$)	TICKER	NAME	1M (%)	3M (%)	12M (%)	MONTHLY VOL (\$)	VOL CHANGE (%)
47	3	\$24.79m	EOF	ECOFIBRE LIMITED	9.7	-32.0	-56.1	\$0.18m	30.15
46	0	\$25.7m	IVX	INVION LIMITED	0.0	25.0	0.0	\$0.26m	564.50
39	9	\$44.15m	BDX	BCAL DIAGNOSTICS LIMITED	88.2	94.4	84.2	\$1.19m	4.26
48	6	\$23.88m	SNT	SYNTARA LIMITED	25.0	-9.1	0.0	\$0.72m	-18.86
45	0	\$26.23m	ATH	ALTERITY THERAPEUTICS LIMITED	0.0	0.0	-28.6	\$1.67m	27.03
49	3	\$23.38m	NOX	NOXOPHARM LIMITED	19.4	-3.6	8.1	\$0.3m	101.31
51	2	\$22.68m	ACR	ACRUX LIMITED	17.4	39.7	76.1	\$0.72m	-80.33
50	-6	\$23.19m	ECS	ECS BOTANICS HOLDINGS LTD	-14.3	-21.7	-18.2	\$0.71m	0.08
52	-3	\$22.12m	IMC	IMMURON LIMITED	-5.1	30.6	22.1	\$0.49m	-53.59
54	6	\$18.2m	ATX	AMPLIA THERAPEUTICS LIMITED	14.8	-11.1	-7.7	\$0.44m	65.99
53	3	\$20.25m	1AI	ALGORAE PHARMACEUTICALS LIMITED	10.0	10.0	10.0	\$0.28m	-20.23
55	4	\$16.66m	OSL	ONCOSIL MEDICAL LTD	0.0	-33.8	-41.2	\$0.7m	34.47
59	-4	\$14.4m	PAB	PATRYS LIMITED	-22.2	-30.0	-12.5	\$0.16m	-5.45
57	-10	\$15.53m	CHM	CHIMERIC THERAPEUTICS LIMITED	-35.7	-33.3	-51.4	\$0.96m	23.31
61	0	\$13.37m	1AD	ADALTA LIMITED	-13.8	8.7	0.0	\$0.48m	-49.16
56	1	\$16.3m	RGT	ARGENT BIOPHARMA LIMITED	-7.5	-17.8	-24.5	\$0.06m	-54.73
60	2	\$14.21m	TRP	TISSUE REPAIR LTD	-6.1	2.2	4.5	\$0.08m	-71.52
68	-5	\$9.05m	NYR	NYRADA INC.	-39.4	-42.4	147.8	\$0.72m	-63.08
62	2	\$13.22m	GTG	GENETIC TECHNOLOGIES LIMITED	-9.1	-16.7	-31.0	\$0.18m	-14.81
63	-5	\$12.68m	AVE	AVECHO BIOTECHNOLOGY LIMITED	-25.0	0.0	0.0	\$0.09m	-72.47
58	-7	\$15.19m	RAD	RADIOPHARM THERANOSTICS LIMITED	-27.3	-52.2	-56.8	\$0.3m	-20.62
65	3	\$10.94m	FRE	FIREBRICK PHARMA LIMITED	0.0	20.0	20.0	\$0.17m	-78.60
64	3	\$12.31m	MEM	MEMPHASYS LIMITED.	12.5	0.0	-30.8	\$0.21m	20.08
66	0	\$10.54m	AGH	ALTHEA GROUP HOLDINGS LIMITED	-6.9	-10.0	-28.9	\$0.36m	167.89
67	2	\$9.17m	ANR	ANATARA LIFESCIENCES LTD	-2.1	80.8	113.6	\$0.09m	-55.01
70	0	\$7.76m	DVL	DORSAVI LTD	-7.1	-13.3	18.2	\$0.11m	-49.96
69	4	\$8.7m	ILA	ISLAND PHARMACEUTICALS LIMITED	26.4	-8.2	-24.0	\$0.41m	6.37
71	3	\$7.23m	NSB	NEUROSCIENTIFIC BIOPHARMACEUTICALS LTD	6.5	0.0	11.4	\$0.17m	-88.08
72	-7	\$6.92m	VBS	VECTUS BIOSYSTEMS LIMITED	-48.0	-48.0	-56.7	\$0.21m	747.19
73	2	\$5.71m	IXC	INVEX THERAPEUTICS LTD	0.0	-1.2	-1.2	\$0.03m	-61.89
74	-3	\$5.33m	ZLD	ZELIRA THERAPEUTICS LIMITED	-30.9	-44.7	-48.1	\$0.11m	333.24
75	-3	\$4.6m	CMB	CAMBIUM BIO LIMITED	-33.3	0.0	50.0	\$0.02m	-93.55
76	1	\$4.13m	NC6	NANOLLOSE LIMITED	9.1	0.0	4.3	\$0.04m	76.09
77	-1	\$3.23m	AN1	ANAGENICS LIMITED	-22.2	-53.3	-65.0	\$0.11m	100.80
78	0	\$1.67m	HXL	HEXIMA LIMITED.	-9.1	-23.1	-44.4	\$0.02m	-66.06

Want to be a top performer?

Our resources that you can leverage to level up your market engagement.

Create a strategy for “the code”.

Running a public company means that you are in charge of two separate, but interconnected businesses. You’ve got the operational business (**the company**) and you’ve got the listed business (**the code**). At InvestorHub, we have found that companies with a dedicated strategy to growing **the code** outperform companies that “let results speak for themselves”.

Don’t let a slow news cycle limit growth.

The most common mistake that biotech executives make is leaving large gaps of silence between news. Biotech companies on InvestorHub are overcoming their slow news cycle by remaining proactive with investor communications, posting leadership updates, investor interviews, and webinars to keep their shareholders informed, reduce the risk of selloffs, and consistently push their **code** to prospective new investors.

It’s about building belief, not understanding.

If you gave me the raw results of a Phase 2 trial, I would have no idea as to whether they were good, bad, or average. Most non-institutional investors are **exactly the same**. Listed companies are complex, and while it’s important to educate your investors to better understand your business, the reality is **most of your shareholders invest based on belief**. That’s why you need to utilise a balanced investor relations approach that builds investor belief in your leadership team and their ability to execute the company strategy.

Communicate always, regardless of your share price.

Most biotech companies take a proactive approach when investor attention is high (normally after positive results or news). But **being proactive** is equally as important when the company, or the market, is on a downturn, because that’s when your shareholders are **most likely to sell**. Investor marketing is a framework that public companies are using to ensure they are consistently communicating with and engaging the market, and in doing so, are outperforming their peers when it comes to shareholder growth and capital raising.

InvestorHub is perfect for Biotech companies.

InvestorHub helps biotech companies overcome slow news cycles and impatient investors to catalyse shareholder growth and optimise raise outcomes. **Talk to us today.**

15% of ASX biotech companies use InvestorHub.

When biotech companies use InvestorHub, it's like adding oxygen to a flame. With 15% of ASX biotech companies using our product, companies on InvestorHub are more likely to be seen and considered by individual investors.

A **discovery call** is the perfect place to start exploring how InvestorHub can uplift your public performance. Our discovery calls are about getting to know you and your business and whether our product is right for you.

No hard sell, no technical jargon, just a friendly chat about you and how we might **make your listed experience better**.

🌐 investorhub.com

➤ clients@investorhub.com

☎ (03) 9661 0441

